Risperidone (Uzedy)

Small molecule

Also known as TV-46000

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (2)
Schizophrenia
Used as active comparator (10)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Bipolar Disorder
NCT00857818 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2009-04 – 2010-03 · Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
What this study did
Phase 2 (2)
Schizophrenia
NCT04624243 · Merck Sharp & Dohme LLC
2020-12-15 – 2024-06-21 · Schizophrenia
What this study did
NCT03055338 · Merck Sharp & Dohme LLC
2017-03-08 – 2018-01-09 · Schizophrenia, Acute Episode
What this study did
Phase 1 (3)
Schizophrenia
NCT05542264 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-11-15 – 2024-02-12 · Schizophrenia
What this study did
NCT05402111 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2022-06-13 – 2023-09-27 · Schizophrenia
What this study did
NCT01376076 · Forest Laboratories
2011-06 – 2012-02 · Schizophrenia
What this study did
Phase 4 (4)
Schizophrenia
NCT02282085 · Matt Byerly
2014-12 – 2017-12 · Schizophrenia
What this study did
NCT00508157 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2007-11-01 – 2009-03-01 · Metabolic Syndrome, Schizophrenia
What this study did
NCT00654576 · Central South University
2005-02 – 2007-12 · Schizophrenia
What this study did
Appears in other studies (35)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (10)
Schizophrenia
NCT06878833 · Lyndra Inc.
2025-04-18 – 2026-12-31 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01370291 · Xijing Hospital
2011-06 – 2013-12 · Schizophrenia
What this study did
NCT00843687 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2005-09 – 2007-03 · Schizophrenia
What this study did
NCT00216580 · Janssen Pharmaceutica N.V., Belgium
2004-02 – 2006-12 · Schizophrenia
What this study did
NCT00828958 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2006-02 – 2006-09 · Schizophrenia
What this study did
NCT00237913 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-07 – 2005-08 · Schizophrenia
What this study did
NCT00034892 · AstraZeneca
2002-03 – 2005-03 · Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
What this study did
NCT00161018 · University of Maryland, Baltimore
2003-11 – 2004-11 · Schizophrenia
What this study did
NCT00159770 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2001-11 – 2004-09 · Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
What this study did
NCT00297388 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
est. completion 2004-09 · Schizophrenia, Schizoaffective Disorder
What this study did
Phase 2 (4)
Schizophrenia
NCT07152184 · University Hospital, Strasbourg, France
2026-10-01 – 2032-02-01 · Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
What this study did
NCT01411085 · Dartmouth-Hitchcock Medical Center
2011-12 – 2014-09 · Schizophrenia, Alcoholism, Dual Diagnosis
What this study did
NCT00509067 · Georgetown University
2007-11 – 2011-03 · Schizophrenia
What this study did
NCT00921804 · AstraZeneca
2009-06 – 2010-05 · Schizophrenia
What this study did
Phase 1/2 (1)
Schizophrenia
NCT02538081 · VA Office of Research and Development
2015-08 – 2016-08 · Schizophrenia
What this study did
Phase 4 (14)
Bipolar Disorder
NCT07047651 · Dr. Stavroula Rakitzi
2025-06-04 – 2027-12-20 · Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
What this study did
Schizophrenia
NCT02040883 · Qingyun Yin
2014-02 – 2014-12 · Schizophrenia
What this study did
NCT01140620 · University of Manchester
2010-06 – 2010-12 · Healthy Volunteers, Schizophrenia
What this study did
NCT00761670 · Sanofi
2008-09 – 2010-01 · Schizophrenia
What this study did
NCT00498004 · Inje University
2007-08 – 2008-09 · Schizophrenia
What this study did
NCT00304616 · Korea Otsuka Pharmaceutical Co., Ltd.
2004-10 – 2007-10 · Schizophrenia
What this study did
NCT00325689 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2006-07 – 2007-10 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00254241 · AstraZeneca
2002-05 – 2006-06 · Schizophrenia
What this study did
NCT00159081 · Heinrich-Heine University, Duesseldorf
2000-11 – 2005-06 · Schizophrenia
What this study did
NCT00157378 · Ludwig-Maximilians - University of Munich
2000-11 – 2004-12 · Schizophrenia, First-Episode
What this study did
NCT00061802 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2003-06 – 2004-02 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT00331825 · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
2000-07 – 2003-07 · Schizophrenia, Extrapyramidal Syndrome
What this study did
NCT00034905 · AstraZeneca
2001-07 – 2002-09 · Schizophrenia
What this study did
Early phase / not applicable (6)
Bipolar Disorder
NCT00179062 · Vanderbilt University
2000-02 – 2007-06 · Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
What this study did
Schizophrenia
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did
NCT00716755 · Centre for Addiction and Mental Health
2009-10 – 2015-08 · Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder, Psychotic Disorder
What this study did
NCT00493233 · Centre for Addiction and Mental Health
2006-11 – 2008-12 · Schizophrenia
What this study did
NCT00225498 · Northwell Health
2002-06 – 2008-10 · Schizophrenia
What this study did
NCT00205738 · Washington University School of Medicine
2000-07 – 2006-10 · Schizophrenia, Type 2 Diabetes Mellitus
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Risperidone (Uzedy): this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.